Evidence map›Paper›PMID 32881478›Full record

ArticleACS chemical neuroscience2020

HMG-CoA Reductase Inhibitors as Drug Leads against

Hye Jee Hahn, Ruben Abagyan, Larissa M Podust, Shantanu Roy, Ibne Karim M Ali, Anjan Debnath

Open access · greenAbstract read
In one paragraph

Article in ACS chemical neuroscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.4field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Approaches for TargetingPathogens (Basel, Switzerland) · 2024
    Review
  3. Article
  4. Frontiers in public health · 2023
    Review
  5. Article
  6. Opportunistic free-living amoebal pathogens.Pathogens and global health · 2022
    Article
  7. Differential Growth Rates andMicrobiology spectrum · 2022
    Article
  8. Article
  9. The therapeutic potential of novel isobenzofuranones against Naegleria fowleri.International journal for parasitology. Drugs and drug resistance · 2021
    Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Hye Jee HahnCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California 92093-0756, United States.
Ruben AbagyanCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California 92093-0756, United States.ORCID 0000-0001-9309-2976
Larissa M PodustCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California 92093-0756, United States.
Shantanu RoyFree-Living and Intestinal Amebas (FLIA) Laboratory, Waterborne Disease Prevention Branch, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia 30329-4018, United States.
Ibne Karim M AliFree-Living and Intestinal Amebas (FLIA) Laboratory, Waterborne Disease Prevention Branch, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia 30329-4018, United States.
Anjan DebnathCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California 92093-0756, United States.ORCID 0000-0001-9294-3927
University of California San Diego · USCenters for Disease Control and Prevention · US

Funding

UC San Diego Clinical and Translational Research InstituteKL2TR001444 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DEPP, COLIN A. · 2015 to 2024
$15.4M
Addressing biomedical challenges with computational mechanics and big dataR35GM131881 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ABAGYAN, RUBEN · 2019 to 2023
$1.9M
Brain Penetrant Microtubule-Stabilizers to Treat CNS-invasive Parasitic DiseasesR21AI141210 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BALLATORE, CARLO, CAFFREY, CONOR · 2019 to 2020
$441k
HMG-CoA Reductase Inhibitors as New Drug Leads for Naegleria InfectionR21AI146460 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DEBNATH, ANJAN · 2020 to 2021
$433k
Brain Penetrant Microtubule-Stabilizers to treat CNS-invasive parasitic diseasesR21AI133394 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BALLATORE, CARLO, CAFFREY, CONOR · 2018 to 2019
$426k
NCATS NIH HHS KL2 TR001444NIAID NIH HHS R21 AI133394NIAID NIH HHS R21 AI141210NIAID NIH HHS R21 AI146460NIGMS NIH HHS R35 GM131881
6 · The paper itself

Abstract

Primary amebic meningoencephalitis (PAM), caused by the free-living ameba

Indexed as

Central Nervous System Protozoal InfectionsHydroxymethylglutaryl-CoA Reductase InhibitorsNaegleria fowleriPharmaceutical PreparationsAdultAustraliaChildHumansHydroxymethylglutaryl-CoA Reductase InhibitorsPharmaceutical Preparationsdrugfree-living amebaHMG-CoA reductaseNaegleria fowleriprimary amebic meningoencephalitisstatins

Identifiers

PMID32881478
PMCPMC7544672
OpenAlexW3083021261

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.